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Summary Misonidazole (MISO) given as a large single dose enhanced the action of cyclophosphamide (Cy)
and melphalan (L-PAM) in two mouse tumours. Below a dose of about 500mgkg-1 it had no
chemosensitizing effect. When MISO was given as a series of small doses by repeat injection over an 8 h
period, in order to simulate human pharmacokinetics, it significantly enhanced the action of Cy in the SA F
tumour. It also enhanced the action of Cy and L-PAM in the WHFIB tumour as assayed by tumour cell
survival in vitro following treatment in vivo but not when the assay was tumour growth delay. There was no
enhancement by MISO of the leukopenia due to Cy or L-PAM. The results suggest that, in some tumours
there may be benefit from the combination of clinically relevant MISO doses with alkylating agents. The
leucopenia induced by these agents should not be enhanced by the MISO.
The electron-affinic radiosensitizer misonidazole
(MISO) has been shown to be a potent enhancer of
the actions of certain chemotherapeutic drugs in
mouse tumours (for review see McNally (1982)). In
general, nitrogen mustards and certain nitrosoureas
appear to be the drugs with which MISO is most
effective. The majority of studies have used single
large doses of MISO and have shown that whilst
there is some enhancement of normal tissue damage
due to the chemotherapeutic drug by MISO, the
enhancement of tumour damage is greater, leading
to a therapeutic gain. The principal exception was
the study of Tannock (1980) who found no
therapeutic benefit from the combination of MISO
with cyclophosphamide (Cy) or BCNU. Law et al.
(1981) suggested that there may be a loss of the
therapeutic gain at high chemotherapeutic drug
doses.
The majority of studies have shown that the
enhancing action of MISO was reduced or lost at
doses within the clinically tolerable range, below
-200mgkg- . However, in the mouse the plasma
half-life of MISO is 40-120min compared with
about 8h in man. This makes the relevance of
single injections of MISO in the mouse to man
difficult to assess. In addition, in vitro studies have
suggested that prolonged incubation with MISO
may be necessary for chemosensitization (Brown,
1982). It is therefore important to simulate in the
mouse the longer half-life of MISO in man in order
todetermine thepossibleclinicalroleofMISOchemo-
sensitization. The first such study was by Brown &
Hirst (1982). They maintained the plasma level of
MISO in mice at about 100ugml-' for 7h using
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repeated injections and obtained drug enhancement
ratios of 1.6 to 2.2 with melphalan (L-PAM) and
Cy in the RIF-1 tumour comparable to those
obtained with large single MISO doses. In contrast,
using nominally the same tumour system but in a
different laboratory, Twentyman & Workman
(1983) have failed to demonstrate significant chemo-
sensitization by similar dosing schedules with
MISO; they only saw an effect when they extended
the exposure to MISO to 16h.
In order to try and understand this confused
situation, we have performed similar experiments
and have measured the response of the WHFIB
mouse tumour to Cy and L-PAM, and the SA F
tumour to Cy, after single and chronic low dosing
with MISO. We have also measured normal tissue
effects in terms of white cell depression following
chemotherapeutic drug treatment.
Materials and methods
Assessment of tumour response
The WHFIB tumour is an anaplastic sarcoma
growing in inbred WHT Gyf BSVS mice. It has
been adapted for growth in vitro so that following
treatment in vivo the response can be measured in
terms of either tumour growth delay or cell survival
in vitro. The methods used to obtain experimental
tumours and to assess cell survival have been
described before (McNally et al., 1979; Martin et al.,
1981). The SA F tumour is a serially transplanted
sarcoma growing in CBA/HtGyfBSVS mice. Both
tumours were implanted by trocar on the lower
backs of 8-12 weeks old mice of the appropriate
strain. Tumours were treated at a mean diameter of
6-7mm. For cell survival studies, WHFIB tumours
() The Macmillan Press Ltd., 1983272 N.J. McNALLY et al.
were excised 24h after giving the cytotoxic drug.
For tumour growth delay studies 6-8 mice were
used for each dose group. The time to grow to 2.5
times the treatment diameter was determined as
previously described (McNally et al., 1979) and
plotted as a function of the cytotoxic drug dose to
obtain dose-effect curves for growth delay.
Drugs
All drugs were dissolved in saline immediately
before use and given i.p. L-PAM was first dissolved
in 0.5ml 2% HCI in ethanol before further diluting.
with saline. Preliminary studies showed that in
order to maintain a plasma concentration of MISO
of l100ygml-1, the following injection schedules
were needed: for WHT mice 120mgkg-' at t=0,
plus 30mgkg-' for every 20min for a total time of
8h; for CBA mice, lOOmgkg-1 at t=0 plus
30mgkg-1 every 20min. The cytotoxic drug was
given immediately after the last dose of MISO.
Leucopenia induced by Cy or L-PAM was
assessed by collecting blood from the carotid artery
after decapitation into a heparinised capillary tube.
The blood was then diluted in 0.2% acetic acid to
lyse the red cells, and the total white cells were
counted using a haemocytometer and phase
contrast microscopy.
Results
Figure 1 shows the effect of varying the dose of
MISO, given as a single injection, on the survival of
WHFIB tumour cells following a single injection of
either l00mgkg-1 Cy (Figure IA) or 5mgkg-' L-
PAM (Figure 1B). The drugs were given 1 h after
the MISO as this has previously been found to be
the optimum time (Martin et al., 1981). For both
cytotoxic drugs the potentiation by MISO
decreased as the MISO dose decreased, so that
below a dose of 500mgkg- 1 with L-PAM, and
300mgkg-1 with Cy, the MISO had no effect.
In order to investigate the effect of chronic low
doses of MISO we adopted the same procedure as
Brown & Hirst (1982) and attempted to maintain a
plasma MISO concentration of 100ugml-1 for 8h.
Figure 2 shows the plasma concentration obtained
for WHT mice (open symbols) and CBA mice
(closed symbols). Each point is the mean from 4-6
mice. The dashed line represents the plasma
concentration in a patient following a single oral
dose of 7g MISO (Urtasun et al., 1977). In fact the
MISO concentration in the WHT mice increased
slightly over the 8h period. At 8h it was
140gmlP -. This concentration could also be
achieved by a single MISO injection of 200-
300mgkg-l. However, as Figure 1 shows, single
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Figure 1 The effect of different doses of MISO on the survival of WHFIB tumour cells following a dose of
(a) 100mgkg-1 Cy or (b) 5mgkg-1 L-PAM. Each point represents the value for an individual tumour
excised 24h after giving the drug.
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Figure 3 Survival curves for WHFIB tumour cells excised 24h after giving varying doses of Cy either alone
or after a single injection of 800mgkg-1 MISO (a) or after chronic dosing with MISO (b). The inset shows
the effect of giving the Cy (100mgkg-1) at the beginning, middle or end of the chronic dosing period. The
lines in this and the next figure have been calculated by linear regression analysis, each point representing an
individual tumour. The mice receiving Cy alone also received appropriate doses of saline.
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Figure 4 Survival curves for WHFIB tumour cells excised 24h after giving varying doses of L-PAM either
alone or after a single injection of 800mgkg-1 MISO (a), or after chronic MISO dosing (b). Mice receiving
L-PAM alone also received appropriate doses of saline.
difference between giving the cytotoxic drugs with
saline or chronic MISO, indicating no potentiation
by chronic MISO.
In view of the difference between the two
methods of assay, which were done using different
batches of tumour transplants, a further experiment
was performed in which tumours from a single
transplant were treated at the same time with
150mgkg-' Cy either alone or with repeated
injections of saline or of MISO and then assayed by
growth delay or cell survival. The results are shown
in Figure 7. As before, there was clear potentiation
by the chronic MISO dose when using the cell
survival assay, but none using growth delay. The
dashed lines in Figure 7 represent the dose-effect
curves previously obtained. In this transplant the
growth delay values were close to the Cy alone
value previously obtained. The cell survival values
for Cy plus chronic MISO are also similar to the
previous values (Figure 3).
In view of the absence of an effect of chronic
MISO dosing on growth delay in the WHFIB
tumour following treatment with Cy or L-PAM, we
treated a different strain of mice (CBA) bearing a
different tumour (SA F) with Cy either alone or
after chronic dosing with MISO for 8h. The
resulting MISO plasma levels are shown in Figure 2
(closed symbols) and over the 8h period averaged
115pgml-'. The resulting growth delay dose-effect
curves are shown in Figure 8. There was clear
enhancement of the action of Cy by the MISO. At
a Cy dose of 150mgkg-' the growth delay was
doubled by the MISO. Overall, the enhancement
ratio was
- 1.5.
In order to try and simulate possible clinical
schedules ofcytotoxicdrugadministration, CBA mice
bearing SA F tumours were given weekly doses ofCy
either alone or 1 h after a MISO dose of 500mgkg- 1,
or immediately at the end of a 3 h chronic MISO
dosing schedule. The MISO injection schedule was
as described above for CBA mice. Fifteen minutes
after the first dose the blood MISO level was
130 pgml-'. Fifteen minutes after the end of the 3 h
injection schedule it was 100pgml-. Treatment
commenced when tumours reached a mean
diameter of 6.5-7.5mm and continued either until
animals had to be sacrificed because tumour growth
was not controlled, or to 3 weeks after tumours
were no longer palpable. The mice were not treated
again if the tumours subsequently regrew.
A weekly dose of Cy of 80mgkg-' was too small
because the tumours grew too large in the first
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Figure 5 Growth delay curves for WHFIB tumours
treated with Cy. Open symbols Cy alone; closed
symbols, Cy plus 800mgkg-1 MISO (a) or chronic
MISO (b). Mice treated with Cy alone received
appropriate doses of saline as well. Error bars, 95%
confidence limits. At least 6 mice per point.
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Figure 6 Growth delay curves for WHFIB tumours
treatedwithL-PAM.(0),L-PAMplusappropriate saline
doses; (0) L-PAM plus 800mgkg- MISO (a) or
chronic MISO (b); (A) L-PAM alone (b). Error bars,
95% confidence limits. At least 6 mice per point.
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Figure 7 A comparison between the cell survival and growth delay assay on a single batch of mice. (O), Cy
alone, (O) Cy plus 800mgkg-1 MISO, (A\) Cy plus chronic saline, (A), Cy plus chronic MISO. The dashed
lines have been redrawn from Figures 3 and 5.
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Figure 8 Growth delay curves for SAF tumours
treated with Cy plus chronic saline (O), or Cy plus
chronic MISO (0). Error bars, 95% confidence limits.
At least 6 mice per point.
week whether or not MISO was given. For a Cy
dose of 120mgkg-t, 12/18 mice were cured. We
therefore combined the MISO with a weekly
Cy dose of 100mgkg-1, which was sufficient to
produce significant growth delay without too many
cures on its own. The resulting growth curves for
individual tumours are shown in Figure 9. Cy alone
cured 1/10 mice with most of the mice having to be
sacrificed within 50 days. Both MISO doses caused
a significant increase in the number of cures, 7/10,
with significantly increased growth delay for the
tumours that did recur (Figure 9). None of the mice
showed any adverse effects of the drug treatments.
The effects of Cy and L-PAM on white cell
depression in mice, either alone or following chronic
MISO doses, are shown in Figure 10. The
measurements were at Day 3 for Cy and Day 5 for
L-PAM, since we have shown previously that these
are the times of maximum white cell depression for
the two drugs (McNally et al., 1982). Each point
represents measurements on 5 mice. MISO had no
effect on Cy or L-PAM induced leucopenia.
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Cy at end
Sarcoma F
Tm.D
Time (d)r
Figure 9 Growth curves for individual SAF tumours treated with 100mgkg- Cy weekly either on its own
or with chronic MISO for 3h or with 500mgkg 1 MISO one hour before.
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Figure 10 The effect of chronic MISO dosing on the
leucopenia induced by (a) Cy or (b) L-PAM in WHT
mice. Five mice per point. Error bars, 95% confidence
limits. Cytotoxic drug plus chronic saline (0);
cytotoxic drug plus chronic MISO (0).
Discussion
Single doses of MISO below 500mgkg-' were
ineffective at enhancing the action of Cy or L-PAM
in WHFIB tumours (Figure 1), but when the
difference in MISO pharmacology between mouse
and man was taken into account by multiple
injections of MISO into mice, it was possible in
some cases to obtain significant enhancement of
drug action by clinically realisable MISO
concentrations (Figures 3, 4 and 8). Indeed, with the
weekly dosing schedule shown in Figure 9,
enhancement of Cy action in the SA F tumour was
obtained when the MISO concentration in the
blood was maintained at lOO1jgml-' for only 3h,
considerably less than in the clinical situation.
We have no explanation for the discrepancy
between the growth delay and cell survival assay in
the WHFIB tumour. There was no obvious
difference in the cell yields in the survival assays.
In order for a difference in cell yields to explain the
results, cells would have to die rapidly from the Cy
alone treatment, so that cell survival assayed at 24h
would underestimate the extent of cell kill (due to
the removal of killed cells), but the chronic MISO
dosing would have to prevent this loss of Cy killed
cells. This seems unlikely. An alternative possibility
is that the chronic MISO dosing delays the onset of
recovery from potentially lethal drug damage but
does not prevent it, so that a delay of 24h before
excising the tumour is not sufficient. This is
certainly not the case for acute doses of MISO
(Martin et al., 1981) and could not apply in the case
of the SA F tumour for which there was clear
enhancement of drug action by chronic MISO
dosing. Another possibility is that prolonged
exposure to low doses of MISO made cells more
susceptible to damage by the disaggregation
procedure. However, there was no effect of the
chronic MISO dosing on the plating efficiency, and
it is difficult to see why this should result in a dose
modifying effect.
Brown & Hirst (1982) using a similar MISO
dosing schedule to the present one obtained
significant enhancement of the action of Cy and L-
PAM in the RIF-1 tumour when measuring growth
delay. However, Twentyman & Workman (1983)
using the RIF-1 and KHT tumours, failed to show
potentiation of the action of Cy, L-PAM,
chlorambucil or CCNU when the blood MISO
concentration was maintained at 100pgml'- for
8h. With Cy they did measure an enhancement
ratio of not more than 1.5 when the MISO was
injected over a 16h period. These variable results,
depending on the tumour system, on the MISO
injection schedule and, in the case of the WHFIB
tumours, on the method of assay, suggest that there
may be a threshold level of MISO which depends
on the tumour type, below which chemosensi-
tization is not seen.
Whereas the radiosensitizing ability of MISO
depends on its concentration in the target cells at
the time of irradiation, i.e. the peak concentration
achievable, chemosensitization depends on
concentration and the overall exposure time, since
by extending the exposure to a low plasma level of
MISO for a long time it is possible to achieve
chemosensitization which would not be seen if the
same plasma level were achieved following a single
MISO dose. The hypoxic cell toxicity of MISO in
vitro also depends on concentration and contact
time (Moore et al., 1976), and Conroy et al. (1980)
have shown significant tumour cytotoxicity of MISO
following i.v. infusion at a variable rate to simulate
human pharmacokinetics. However, there is no
clear evidence of significant MISO toxicity in
human tumours (Denekamp & McNally, 1978) and
neither we nor Brown & Hirst (1982) have seen
anything but minimal MISO cytotoxicity in our
tumours. Thus, it would seem that MISO is truly
enhancing drug action and the mechanism is
probably not related to its hypoxic cell cytotoxicity.
We have shown that large acute doses of MISO
can significantly alter the pharmacokinetics of Cy
and L-PAM (Hinchliffe et al., 1983) and this could
account for the enhancing effect of large doses of
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MISO. The same cannot be true for chronic MISO
doses, since they had no effect on drug
pharmacology (Hinchliffe et al., 1983). Brown (1982)
has suggested two possible mechanisms for the
enhancement of cytotoxic drug action by MISO.
These are the reduction in the concentration of
non-protein sulphydryls which occur in hypoxic
cells, and the enhanced formation of DNA
interstrand cross-links formed by L-PAM, which
can lead to increased cell killing (Brown, 1982;
Taylor et al., 1982).
The lack of drug enhancement of the leucopenia
due to Cy and L-PAM by chronic dosing with
MISO (Figure 10) is in agreement with our
previous finding that acute doses of MISO also had
no effect (McNally et al., 1982). Brown & Hirst
(1982) also found no enhancement of normal tissue
toxicity by chronic MISO doses. We did not
measure normal tissue effects in the weekly dosing
study with SA F (Figure 9). However, there was no
weight loss of the mice treated with the Cy whether
or not they received MISO, and there were no
outward signs of toxicity.
The fractionation study with the SA F tumour
shows that where the chemotherapeutic drug is
having an effect (1/10 mice cured), the addition of
MISO can significantly increase the effectiveness of
the drug (seven out of ten mice cured), although the
actual enhancement ratio may be quite small. This
was with a clinically realisable plasma MISO
concentration, but a much shorter MISO exposure
time than in man. More studies are needed to try to
understand the differing responses of experimental
tumours to the combination of low chronic
MISO doses and drugs. The absence of increased
normal tissue damage due to the MISO is
encouraging and, combined with the positive
benefits in certain tumours, suggests that there
could be benefit from the combination of MISO
and certain chemotherapeutic drugs in man,
particularly when the human tumour shows a
response to the drug.
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